American Association for Cancer Research Elects SKCC Director Karen Knudsen to Board of Directors

29
Mar

The members of the American Association for Cancer Research (AACR) have elected Karen E. Knudsen, PhD, Executive Vice President of Oncology Services and Enterprise Director of the Sidney Kimmel Cancer Center – Jefferson Health (SKCC) to its Board of Directors. Knudsen is one of five world-renowned cancer researchers elected to the board for the 2019-2022 term.Dr. Karen Knudsen

Based in Philadelphia, the AACR is the world’s first and largest professional organization dedicated to advancing cancer research. Membership includes more than 42,000 laboratory, translational and clinical researchers; population scientists; patient advocates; and other health care professionals from 120 countries.

“As Enterprise Director of a highly ranked, NCI-designated cancer center, I am acutely aware of the vital role that the AACR plays in the cancer research and care community. My vision as a member of the Board of Directors is to assist the AACR in meeting its mission to prevent and cure cancer, achieved through the lens of my expertise in leading multidisciplinary cancer care and research teams,” Knudsen said.

“Moreover, it is my hope to leverage expertise in engaging the non-scientific community in the AACR’s mission, including patients, caregivers, advocates and legislatures. Working together, the AACR will continue to lead in reducing the cancer burden.”

Knudsen oversees cancer care and cancer research at all SKCC-Jefferson Health sites within the Greater Philadelphia region. She also serves as Chair of the Department of Cancer Biology for Thomas Jefferson University, and holds the Hilary Koprowski Endowed Professorship and joint appointments in the Departments of Medical Oncology, Urology, and Radiation Oncology. Her translational research centers on prostate cancer and has contributed to new mechanisms for treatment of advanced disease.

Knudsen is also Vice President/President-Elect of the Association of American Cancer Institutes (AACI), an appointed member of the NCI’s Board of Scientific Advisors, and editor-in-chief of Molecular Cancer Research. Previous national leadership positions include chair and member of the AACR Nominating Committee and member of the AACI Board of Directors.

“Dr. Knudsen is a triple-hitter in cancer—she conducts research, she understands the urgency of care, and she is committed to improving life in our community,” said Stephen K. Klasko, MD, MBA, president of Thomas Jefferson University and CEO of Jefferson Health. “My deepest congratulations go to her, and I appreciate the honor AACR bestows in electing her to its Board of Directors.”

She will officially begin the 2019-2022 term during the AACR Annual Meeting, which is being held in Atlanta, March 31-April 3.

Read more about the AACR Board of Directors and new leadership here.